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Recombinant lentiviral vectors pseudotyped with heterologous HIV-1 envelope glycoproteins allow rapid and accurate measurement of
antibody-mediated HIV-1 neutralization. However, the neutralization phenotypes of envelope pseudoviruses have not been directly compared
to isogenic replication competent HIV-1. We produced pseudoviruses expressing three different HIV-1 envelope glycoproteins and subcloned
the same three env genes into a replication competent NL4-3 molecular clone. For each of the antibodies tested, the neutralization dose–
response curves of pseudoviruses and corresponding replication competent viruses were similar. Thus, envelope pseudoviruses can be used to
study the anti-HIV-1 neutralizing antibody response. A single passage of replication competent virus derived from 293T cells through
peripheral blood mononuclear cells (PBMC) caused a substantial decrease in sensitivity to neutralizing antibodies. This was associated with
an increase in average virion envelope glycoprotein content of the PBMC-derived virus. Replication competent HIV-1 and isogenic envelope
pseudoviruses have similar neutralization characteristics, but passage into PBMC is associated with decreased sensitivity to neutralization.
Published by Elsevier Inc.Keywords: HIV-1; Vaccines; Neutralizing antibodies; PseudovirusIntroduction
Virus neutralization assays are designed to measure a
reduction in viral infectious titer mediated by antibody.
Since HIV-1 can be readily cultured in activated human
peripheral blood mononuclear cells (PBMC), virus stocks
are often derived from the supernatant of infected PBMC0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.06.003
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E-mail address: jmascola@nih.gov (J.R. Mascola).cultures. HIV-1 strains originally isolated on and cultured
only in PBMC are referred to as primary isolates to
distinguish them from HIV-1 adapted to grow in continuous
T-cell lines. HIV-1 neutralization assays using PBMC-
derived viruses and PBMC target cells have provided
important information about the relative neutralization
resistance of primary isolates compared to prototypic
laboratory adapted strains of HIV-1 (Mascola et al., 1996;
Montefiori et al., 1996; Moore et al., 1995; Wrin et al.,
1995). In addition, PBMC neutralization assays were used
in conjunction with passive antibody infusion studies to05) 226 – 238
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models corresponded to the level of neutralizing antibodies
present at the time of challenge (Baba et al., 2000; Mascola
et al., 2000; Parren et al., 2001; Shibata et al., 1999).
Despite biologically relevant features of this assay
approach, there are several disadvantages inherent in the
use of PBMC-cultured virus for neutralization assays. The
molecular quasispecies present in cell cultured virus makes
it difficult to know the precise protein sequence of the HIV
gp160 and limits studies that attempt to map neutralization
activity to well-defined neutralization epitopes on the
envelope glycoprotein. Additionally, the cultured viral
quasispecies can change subtly with serial viral passage,
which is not readily detected without full-length env gene
sequencing. Finally, the host PBMC used to make new virus
come from various individual donors, resulting in lack of
consistency in biological characteristics such as viral titer
and viral incorporation of cell surface molecules (Bounou et
al., 2004; Giguere et al., 2004). These characteristics likely
impact the precision and reproducibility of PBMC neutral-
ization assays, rendering such assays difficult to apply to
clinical trials where good laboratory practices and validated
assays are required (Li et al., in press; Mascola et al., in
press; Moore and Burton, 2004). In contrast, assays using
viral molecular clones have several advantages. The
envelope glycoprotein amino acid sequence is precisely
known and exists in a stable DNA plasmid form, and the
generation of new virus stocks requires only transfection of
a suitable mammalian cell line, such as 293T cells. Since
fully infectious molecular clones of HIV-1 are not readily
isolated or constructed, an alternate approach for neutraliza-
tion assays involves the construction of Env-pseudotyped
viral vectors that incorporate the Env protein of choice
(Connor et al., 1996; He et al., 1997; Li et al., in press;
Quinnan et al., 1998; Sullivan et al., 1998). Such
recombinant Env pseudoviruses are commonly made by
co-transfection of an env-defective HIV-1 molecular clone
together with an expression plasmid encoding the Env of
interest. The resulting viral vector is capable of a single
round of infection and can be engineered to carry a reporter
gene, such as green fluorescent protein or luciferase, that
facilitates the quantification of infection. Viral vectors
pseudotyped with mutant Env proteins have been used
extensively to map the interaction of HIV-1 envelope
glycoproteins with cellular receptors and to map binding
regions of anti-HIV-1 neutralizing antibodies (He and
Landau, 1995; Kolchinsky et al., 2001a,b; Park et al.,
1998; Sullivan et al., 1998). Since full-length Env genes can
be readily amplified from plasma or primary patient PBMC,
these vectors have also facilitated our understanding of the
development and escape from neutralizing antibodies
directed against autologous virus (Richman et al., 2003;
Wei et al., 2003).
The advantages of Env-pseudotyped viral vectors make
them a preferred reagent for standardized neutralization
assays (Li et al., in press; Moore and Burton, 2004).However, the neutralization phenotype of Env-pseudotyped
viral vectors has not been directly compared to replication
competent viruses expressing the same envelope glycopro-
tein sequences. Addressing this question would provide
useful interpretive context for results obtained in neutraliza-
tion assays using Env-pseudotyped viral vectors. We there-
fore constructed three Env expression plasmids that were
used to make pseudoviral vectors. The same env genes were
also inserted into the NL4-3 infectious molecular clone
(IMC) to make the corresponding chimeric IMC. We also
prepared PBMC-derived IMCs by short-term passage
through PBMC of virus derived from transfection of 293T
cells. This enabled us to compare the neutralization
characteristics of replication competent and Env-pseudo-
typed viruses that encoded the same envelope glycoprotein
and to compare the properties of viruses produced from
infectious molecular clones following transfection of 293T
cells or infection of PBMC.Results
Generation of virus stocks
Envelope genes from three viruses were used in this
study. HIV-89.6 is a well-characterized infectious molecular
clone that preferentially uses coreceptor CXCR4 but can
also use CCR5 and infects macrophages as well as T-cells
(Collman et al., 1992; Smyth et al., 1998). HIV-BL01 and
BR07 were cloned directly from blood and brain tissue,
respectively, of two HIV-1-infected patients with late stage
disease (Ohagen et al., 2003). HIV BL01 preferentially uses
CXCR4, and HIV BR07 can enter cells by either CCR5 or
CXCR4. Fig. 1A shows a schematic of the protocol used to
produce the replication competent IMCs derived directly
from transfection of 293T cells (IMC-293T) as well as the
corresponding Env-pseudotyped viruses, also derived from
293T cells. Also shown are virus stocks derived from a
single passage of the IMC-293T virus through PBMC, now
designated as IMC-PBMC virus. Prior to performing
neutralization assays, each virus stock was titrated to
determine a dilution that resulted in the infection of
approximately 1% to 2% of the target CD4 T-cells. As an
example, Fig. 1B shows the flow cytometric plots of the
number of T-cells infected by each of the three virus stocks
of HIV-89.6. This normalization of viral input allowed
comparisons of the neutralization characteristics of each
viral stock.
Comparison of IMC-293T and Env pseudoviruses
We first compared the neutralization sensitivity of the
Env pseudoviruses to their isogenic replication competent
IMCs (Fig. 2). Both the IMC-293T and the pseudoviruses
were derived from transfection of 293T cells, and, in each
case, the virus was harvested approximately 48 h after
Fig. 1. (A) Generation of virus stocks. The replication competent Env-chimeric infectious molecular clones were derived from transfection of 293T cells
(IMC-293T) and by one additional 4- to 6-day passage into PBMC (IMC-PBMC). The corresponding Env pseudovirus contains the same env gene sequence
as the IMCs. To produce Env pseudoviruses, we used a fixed ratio of Env backbone plasmid to the Env expression plasmid (5:1 by weight). This ratio was
shown to produce Env pseudovirus stocks with the highest level of cell entry. (B) Neutralization assays for each virus stock were performed with a viral
inocula that produced single-round infection of approximately 1% of CD4 T-cells, as measured by flow cytometry. Fifty thousand events were counted, and
infected cells were gated as shown. T-cell infection by the IMCs was measured by intracellular staining for p24-Gag. Infection by the Env pseudovirus was
assessed by expression of GFP.
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and Env pseudovirus had similar neutralization character-
istics. The shapes of the dose–response curves were
similar, and the measured IC50s were within 4-fold of
each other in most cases (Table 1). In several cases, the
IMCs appeared to be modestly more neutralization-sensi-
tive than the corresponding Env pseudovirus, but this was
only significant (i.e., greater than 4-fold) for several
antibody–virus combinations (shown as underlined values
in Table 1). We chose a 4-fold difference in the IC50 values
as a generally accepted value that depicts a meaningful
difference in antibody potency. Since the IC50 values were
derived by fitting the antibody dose–response curves with
a four-parameter logistic equation, it is possible to
calculate the standard error and confidence interval of
each IC50 value. This was done using GraphPad Prism
software and the analysis showed that dose–response
curves with IC50 values that differed by four-fold met
criteria for statistically significant differences (P < 0.01).
Table 1 shows the IC50 values for all virus and antibody
pairs tested, including those for an additional anti-V3 mAb
designated as mAb 2442.Comparison of IMC-293T to IMC-PBMC
HIV-1 is often cultured in PBMC, and many neutraliza-
tion assays are done with HIV-1 derived from the super-
natant of infected PBMC. We passaged the IMC-293T
viruses through activated PBMC (for 4 to 6 days) and
compared the resulting virus (IMC-PBMC) to the parental
IMC derived by direct transfection of 293T cells. Fig. 3
shows that the PBMC-derived IMCs were substantially less
sensitive to neutralization than the corresponding isogenic
IMC-293T viruses. This decreased sensitivity for IMC-
PBMC virus was observed, to some degree, with all
antibodies tested. Thus, the effect appeared to be rather
global and not limited to specific neutralization epitopes.
Interestingly, the reduction in sensitivity to neutralization by
sCD4 was less than that seen for the anti-HIV-1 antibodies.
To confirm that the altered neutralization phenotype of the
IMC-PBMC viruses was not due to genetic changes caused
by short-term PBMC culture, we directly sequenced proviral
DNA from PBMC harvested the same day that virus
supernatant was collected. For each of the three viruses,
the full env gene sequence of the IMC plasmid was identical
Fig. 2. Neutralization dose– response curves for HIV-1 BL01 (A), BR07 (B) and 89.6 (C). Figures show a comparison of IMC-293T (4) to Env pseudovirus
(n). Error bars show the mean (+/ SEM) for two to four independent experiments for each antibody–virus combination. In some cases, data are derived from
a single experiment, and no error bars are shown (e.g., for sCD4).
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Table 1
Neutralization IC50 values (Ag/ml)
BL01 BR07 89.6
Env-PV IMC-293T IMC-PBMC Env-PV IMC-293T IMC-PBMC Env-PV IMC-293T IMC-PBMC
HIVIG 284 145 685 144 76 159 131 37 134
2F5 0.43 0.22 3.1 0.20 0.11 1.4 0.29 0.12 1.9
4E10 0.11 0.03 0.7 0.34 0.30 1.7 0.39 0.36 3.7
2G12 2.5 1.2 >50 7.6 0.49 >50 0.48 0.02 56
b12 2.9 1.9 12 1.0 0.28 0.61 0.11 0.01 0.3
447 >50 >50 >50 11 3.5 45 0.13 0.02 0.6
2442 >50 >50 >50 >50 >50 >50 0.82 0.17 2.9
sCD4 0.49 0.32 0.88 0.09 0.10 0.18 0.04 0.02 0.09
Note. The neutralization dose– response curve for each antibody–virus combination was derived by averaging 2 to 4 independent experiments. The exceptions
are data for sCD4, and in some cases mAb 4E10, that result from a single experiment. IC50 values were calculated by nonlinear regression analysis of the mean
dose– response curve for each antibody–virus combination. Underlined values for IMC-PBMC viruses indicate that the IC50 value was at least 4-fold greater
than the corresponding IC50 value for the IMC-293T virus. In some cases, the IC50 values for the Env-pseudovirus (denoted in table as Env-PV) and IMC-
293T virus differed by greater than 4-fold, and these are also underlined.
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Additionally, we verified that the env gene sequence of the
pSVIII Env expression plasmids for 89.6, BL01 and BR07
was identical to the published sequence and to the IMC
plasmid for each virus (data not shown). Thus, these viruses
were isogenic in env, and the less sensitive neutralization
phenotype of IMC-PBMC virus was not due to genetic
alterations caused by short-term culture.
Biochemical analysis
Fig. 4 shows results from SDS-PAGE analysis of viral
proteins from the purified IMC-293T and IMC-PBMC virus
preparations, but not for the Env pseudoviruses. For all three
of the Env-pseudotyped viral stocks, there was substantially
less virus obtained, based on cell free p24 antigen content
and the level of infectious virus per milliliter, compared to
the IMC-293T and IMC-PBMC virus stocks; these pseudo-
virus preparations contained insufficient material for bio-
chemical analysis. For the IMC-293T and IMC-PBMC virus
preparations, the gp120 and p24 content of the stocks could
be estimated (Fig. 4 and Table 2). Densitometric analysis of
the fluorescent dye-stained bands corresponding to gp120
and p24 for a given sample allows semiquantitative
estimation of p24 and gp120 mass content by interpolation
of the integrated fluorescence values measured for the
relevant bands from the test samples onto a standard curve
generated from the values obtained for known amounts of
purified standard preparations of each protein. As staining
with these dyes is based on the mass of protein or
glycoprotein present, normalization for the molecular
weight of each allows comparison of the relative molar
amounts of each protein present and calculation of the molar
Gag:Env ratio for the sample as an index of the average
envelope glycoprotein content of the virions in the
population sampled. Gag:Env ratios determined by this
method for the well-characterized control virus preparations
HIV-1mn/H9 cl.4 and SIVmne/HuT-78 cl.E11S showedexcellent agreement with previously published results
obtained by quantitative amino acid analysis of HPLC
fractionated proteins from the virus preparations and were in
the expected ranges of 60:1 and 6:1, respectively (Chertova
et al., 2002; Zhu et al., 2003).
For all three viruses tested, the PBMC-produced virus
had higher relative gp120 content and a correspondingly
lower Gag:Env ratio, compared to the corresponding IMC-
293T virus (Fig. 4 and Table 2). For the viruses produced
from a given cell source (PBMC or 293T), the Gag:Env
ratios are roughly comparable for the three different isolates.
We have previously reported that most HIV-1 and SIV
strains have an average Gag:Env ratio of approximately
60:1 (mol/mol), corresponding to about 7 to 14 envelope
trimers per virus particle, based on an estimate of
approximately 1400 gag molecules per virion (Chertova et
al., 2002; Zhu et al., 2003). Thus, the PBMC-derived virus
stocks examined here appear to have slightly more than this
level of envelope glycoprotein, while the 293T-cell-derived
viruses have substantially less. Results obtained using
Coomassie brilliant blue staining were similar. Immunoblot
data were also consistent with results obtained by fluores-
cent protein staining, showing decreased relative amounts of
both gp120 and gp41 compared to p24 for 293T produced
samples vs. PBMC-derived viruses (data not shown). In
previous studies, we used quantitative amino acid analysis
of HPLC fractionated gag and env proteins from virus
samples to more precisely estimate their Gag and Env
content and Gag:Env ratios (Chertova et al., 2002, Zhu et
al., 2003). However, silver-stained gel analysis of HPLC
fractions containing the viral envelope glycoprotein peaks
demonstrated that virion-associated gp120 could not be
clearly resolved from contaminating cellular proteins, which
precluded accurate quantitative amino acid analysis (data
not shown). However, the small size of the Env peaks,
relative to peaks for the gag proteins detected by this
approach, was consistent with the gp120 content and
Gag:Env ratios determined by gel analyses.
Fig. 3. Neutralization dose–response curves. Comparison of IMC-293T (4) to IMC-PBMC (open symbols). Error bars show the mean (+/ SEM) for two to four
independent experiments for each antibody–virus combination. In some cases, data are derived from a single experiment, and no error bars are shown (e.g., for sCD4).
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Table 2
p24CA and gp120SU content, Gag:Env molar ratio and estimated trimers per
virion for 293T and PBMC-produced virus
gp120
(ng)
gp120
(mol)
p24
(ng)
p24
(mol)
p24CA/
gp120SU
mol/mol
Trimers
per virion
(1400 Gag/
virion)
HIV-1 mm 19 0.16 221 9.2 58 8
SIVmneE11S 27 0.23 44 1.6 7 67
HIV-1 89.6/293T 4 0.12 544 22 181 2.6
HIV-1 89.6/PBMC 39 0.33 201 8.4 25 19
HIV-1BR07/293T 4.9 0.04 570 23 580 1
HIV-1 BR07/PBMC 36 0.30 180 7.5 25 19
HIV-1 BL01/293T 3.4 0.03 522 21 762 1
HIV-1 BL01/PBMC 23 0.19 179 7.5 39 12
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Analysis of HIV-1 neutralization is an important aspect
of vaccine development efforts. New single round assays of
viral infection based on Env-pseudotyped lentiviral vectors
are coming into increasingly widespread usage. While
numerous prior studies have used HIV-1 Env-pseudotyped
vectors to generate data on antibody recognition of the
envelope glycoprotein and to study the mechanism of
antibody-mediated viral neutralization (Connor et al.,
1996; He et al., 1997; Kolchinsky et al., 2001a,b; Li et
al., in press; Park et al., 1998; Quinnan et al., 1998; Sullivan
et al., 1998; Richman et al., 2003; Wei et al., 2003), the data
presented here are the first to directly compare the
neutralization phenotype of recombinant pseudotyped vec-
tors to that of Env isogenic replication competent HIV-1. We
show that the sensitivity to neutralization by various
antibody reagents and to sCD4, as well as the overall shape
of the neutralization curves, is similar for Env-pseudotyped
viruses and chimeric IMCs expressing the same envelope
glycoproteins. Pseudoviral vectors have important practicalFig. 4. Fluorescent-stained SDS-PAGE analysis of viral proteins from purified ly
Pro-Q Emerald (green) staining to detect and quantitate glycoproteins and SYPRO
three viruses studied (89.6, BR07, BL01), panel (A) displays results for matched v
the bright gp120 envelope glycoprotein bands for the PBMC-derived virus prep
derived viruses, relative to the comparable p24 capsid bands for each virus pre
characterized reference viruses with known Gag:Env ratios and dilutions of quant
were used to make quantitative estimates of the Gag:Env ratios. Measurements we
gp120 or p24 amount and integrated fluorescence intensity for the corresponding
and gp120 allows estimation of Gag:Env ratio as an index of average virion envelo
panels (B) and (C) include molecular weight standards (MW std), HIV-1mn/H9 cl.4
(Gag:Env mass ratio ¨1:1, molar ratio, ¨6:1); and quantified purified gp120 or p2
immunoblot (data not shown), are seen for some samples. Where gp160 bands we
band only.advantages for performing neutralization assays, and our
data support the use of such viral vectors for standardized
HIV-1 neutralization assays.
The Env-pseudotyped reporter viruses used in this study
express GFP upon infection of target CD4+ T-cells. We used
a flow cytometric assay to enumerate the number of targetsed virus preparations. The figures show superimposed images for SYPRO
Ruby (red) for detection and quantitation of total protein. For each of the
irion preparations derived from 293T cells or PBMC, in adjacent lanes. Note
arations compared to the less prominent gp120 bands for matching 293T-
paration. The gels shown in panels (B) and (C) include samples of well-
ified purified standards for gp120 and p24, along with the test viruses, and
re made under non-saturating conditions where a linear relationship between
bands could be obtained. Comparison of relative intensity of bands for p24
pe glycoprotein content for the virus population sampled. Controls lanes for
(Gag:Env mass ratio ¨10:1, molar ratio, ¨60:1); SIVmne/HuT-78 cl.E11S
4 (see lane labels for amounts). Gp160 precursors, also reactive by anti-Env
re present, calculations were based on integrated fluorescence for the gp120
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study the corresponding replication competent chimeric
IMCs. For the IMCs, we used a protease inhibitor to prevent
secondary rounds of replication and intracellular detection
of p24-Gag antigen to quantify infected T-cells. We have
previously shown that intracellular p24-Gag expression
corresponds to GFP expression for Env reporter viruses
(Mascola et al., 2002). Thus, we know that these two
methods accurately detect first round infection of target
cells. Furthermore, we normalized viral infection of target T-
cells such that approximately 1% to 2% of cells were
infected by either the IMC or Env-GFP (Fig. 1). Under these
conditions, the neutralization curves shown in Fig. 2
demonstrate substantial similarities in the neutralization
phenotype of Env pseudoviruses and corresponding chi-
meric IMCs. In some cases, the sensitivity of the IMC was
slightly greater than the corresponding pseudovirus, though
the IC50 values were generally within four-fold of each
other. However, for HIV-89.6, the IMC-293T was signifi-
cantly more sensitive (i.e., more than 4-fold) than the Env
pseudovirus to several antibodies tested (Fig. 2C). We do
not have a sound explanation for these differences, and since
we were unable to biochemically characterize purified virus
from the Env pseudovirus cultures, we do not have data on
their Env content or quality. Despite these occasional
differences, we believe that the overall similarity in
neutralization sensitivity and the shape of the neutralization
curves indicates a substantial similarity in the neutralization
phenotype of Env-pseudotyped and matched replication
competent clonal viruses. Of note, we optimized the
transfection protocol for Env pseudoviruses in order to
maximize the amount of infectious pseudovirus produced
(that is, a 5:1 ratio of the Env backbone plasmid to the Env
expression plasmid consistently produced the most infec-
tious viral stocks). We did not explore the effect of varying
the transfection conditions on neutralization phenotype of
Env pseudoviruses. It is possible that differences in the
transfection protocol could lead to changes in total Env
incorporation or in Env processing and, thus, differences in
neutralization sensitivity.
In contrast to the similarities between Env pseudoviruses
and IMC derived from 293T cells, we observed a marked
change in neutralization phenotype after a single passage of
293T cell-derived IMC virus through mitogen-stimulated
PBMC (Fig. 3). The observed global change in neutraliza-
tion sensitivity, in the absence of Env sequence changes,
strongly suggests a producer cell effect on neutralization
phenotype. Possible factors that could affect viral neutral-
ization phenotype include the level of envelope glycoprotein
incorporation into the virion, relative efficiency of gp160
cleavage to gp120 and gp41, Env glycosylation patterns and
virion incorporation of producer (host) cell proteins such as
adhesion molecules. We were unable to generate sufficient
material to quantitatively characterize the Env pseudovi-
ruses, and thus we have no data on Env incorporation onto
pseudoviruses. However, we did biochemically character-ized the relative level of envelope incorporation onto 293T
and PBMC-produced viruses. Prior studies have shown that
HIV-1 virions contain between 7 and 14 Env glycoprotein
spikes, though an unknown fraction of these could be non-
functional (Chertova et al., 2002; Layne et al., 1992; Zhu et
al., 2003). In our virus preparations, PBMC-passaged
viruses contained between 12 and 19 Env spikes per virus,
a number consistent with prior estimates for HIV-1.
However, the average value of Env spikes for the IMC-
293 viruses was between one and three. This low value was
somewhat surprising to us, and we do not know if this
average represents a range that includes some virions with
substantially more Env spikes per virion. Nonetheless, our
data suggest that there are more functional trimers on
PBMC-derived viruses, which may contribute to the
observed decrease in their sensitivity to neutralizing anti-
bodies. Of note, the calculation of Env:Gag ratio is based on
gp120 content measured on SDS-PAGE gels. Thus, the
greater Env content of PBMC viruses could also be
explained by more efficient gp160 cleavage that leads to a
larger amount of measured gp120 on our quantitative gels.
Confirmation of this possibility requires further studies.
Biochemical differences in HIV-gp160 related to the cell
origination of the virus have been previously described.
Willey et al. compared macrophage- and PBMC-derived
isogenic HIV-1 (Willey et al., 1996). They found that the
asparagine-linked carbohydrates on macrophage-derived
HIV-1 contained lactosaminoglycans, whereas this was not
observed on PBMC-derived HIV-1. Interestingly, the
macrophage-derived HIV-1 were also 8- to 10-fold more
resistant to polyclonal anti-HIV-1 sera. Thus, the cell from
which HIV-1 is derived can affect biochemical and antigenic
properties of the virus. The potential effect of total Env
incorporation on neutralization sensitivity has been modeled
by Klasse et al. Their model included factors such as
antibody affinity, the number of Env molecules required for
cell attachment and fusion and the number of Env molecules
on the viral surface. In combination, these factors could
account for the marked difference between the highly
neutralization-sensitive T-cell-line-adapted virus strains
and primary PBMC-derived HIV-1 isolates (Klasse and
Moore, 1996). Additionally, Yang, Sodroski and colleagues
have recently used heterotrimers on Env pseudoviruses to
study the stoichiometry of antibody neutralization and have
reported that an HIV-1 virion is neutralized when each Env
trimer on the virion is bound by at least one antibody. In
total, these data support the possibility that the relative
resistance of our PBMC-derived IMCs was due to the
increased level of Env incorporation. However, our data do
not provide direct evidence that the level of Env incorpo-
ration is the determining factor in neutralization sensitivity.
Host cell proteins incorporated during viral assembly and
budding can also affect virus neutralization. These proteins
can increase virion binding to target cells through inter-
actions with their cognate ligands and thereby may enhance
viral infection of target cells and alter neutralization
M.K. Louder et al. / Virology 339 (2005) 226–238234sensitivity (Bounou et al., 2002; Esser et al., 2001; Fortin et
al., 1997; Gomez and Hildreth, 1995; Hioe et al., 2001;
Rizzuto and Sodroski, 1997; Tardif and Tremblay, 2003).
Host cell membrane proteins that are incorporated into virus
particles include ICAM-1, LFA-1, MHC class II isoforms,
CD28 and B7.2 (Arthur et al., 1992; Bastiani et al., 1997;
Bounou et al., 2001; Cantin et al., 1997; Esser et al., 2001;
Fortin et al., 1997; Giguere et al., 2002). Mitogen-stimulated
T cells express these molecules, whereas 293T cells do not
express MHCII, ICAM-1, LFA-1, B7.1, B7.2 or CD28
(Martin et al., 2005; Martin and Tremblay, 2004; Paquette et
al., 1998). Thus, HIV-1 derived from mitogen-stimulated T-
cells contain a greater repertoire of host cell proteins that
likely enhance viral infectivity than virus derived from 293T
cells. Incorporation of host adhesion molecules that increase
viral binding to target cells may decrease sensitivity to
neutralizing antibody. This explanation would be consistent
with the global effect on virus neutralization observed in our
studies. Consistent with this interpretation, a study by
Sawyer and colleagues suggested that short-term passage of
a T-cell-line-adapted virus through PBMC resulted in
decreased neutralization sensitivity of some viruses (Sawyer
et al., 1994). Long-term culture of HIV-1 in PBMC for
many weeks can result in genetic and antigenic changes in
the virus that are associated with an increased sensitivity to
antibody-mediated neutralization (Pugach et al., 2004), but
as noted, our short-term passage into PBMC (4 to 6 days)
was not associated with any changes in Env sequence.
There is an emerging scientific consensus to standardize
HIV-1 neutralizing antibody measurements by using clonal,
single round of replication Env pseudoviruses. A reference
panel of functional clade B Env clones has already been
characterized and made available through the NIH AIDS
Reference and Reagent Repository, and similar reference
strains from non-clade B are currently being constructed (Li
et al., in press; Mascola et al., in press). One concern about
the use of Env pseudoviruses is that the virions are derived
by a transfection process that provides Env in trans, and this
might affect the biochemical or antigenic properties of the
envelope glycoprotein that is incorporated onto these
pseudoviruses. Our data showing that Env pseudoviruses
and IMCs, each derived from 293T cells, were qualitatively
and quantitatively similar with respect to antibody-mediated
neutralization argue against major functional or antigenic
differences in Env properties. Thus, the data reported here
support the use of Env pseudoviruses to measure HIV-1
neutralization. However, an additional concern is that Env
pseudoviruses are more sensitive to neutralization than
PBMC-derived viruses. Here, it is important to note that,
while Env pseudoviruses were generally more sensitive to
neutralization than the corresponding PBMC grown virus,
these differences appeared to be quantitative rather than
qualitative. As an example, resistance to neutralization by
anti-V3 mAb 447 was an inherent property of HIV-1 BL01,
regardless of cell type used to grow the virus. In contrast,
HIV-89.6 was sensitive to neutralization by mAb 447 as anEnv pseudovirus and as an IMC derived from PBMC. In
general, the shape of the neutralization curves was similar
for the pseudovirus and the PBMC-derived virus, and the
difference in neutralization sensitivity was due to a shift in
the neutralization curve. Interestingly, the susceptibility to
neutralization by sCD4 was unchanged by short-term
passage in PBMC. Finally, the data reported by Li,
Montefiori and colleagues suggest that Env pseudoviruses
are not unusually sensitive to neutralization by anti-V3
antibodies or to sera from gp120-vaccinated subjects (Li et
al., in press). Thus, unlike T-cell-line-adapted viruses that
are highly sensitive to sCD4, anti-V3 mAbs and to
antibodies elicited by gp120 immunization, Env pseudovi-
rus maintains a relative resistance to antibody-mediated
neutralization that is characteristic of primary isolates of
HIV-1.
In summary, replication competent chimeric IMCs, and
their corresponding isogenic Env pseudoviruses, were
evaluated for neutralization sensitivity to sCD4, HIV-1
mAbs and HIVIG. Dose–response neutralization curves
displayed a similar shape and IC50 for the matched IMC-
293T and Env pseudoviruses, indicating a similar neutral-
ization phenotype. A single passage of an IMC derived from
293T cells through activated PBMC caused a significant
decrease in viral sensitivity to neutralizing antibodies. This
change appeared to be a host cell effect, as there were no
genetic alterations in the virus following short-term PBMC
culture of the IMC. The decrease in neutralization sensi-
tivity of PBMC-derived virus was associated with higher
levels of envelope glycoprotein incorporation into virions,
but whether this mechanism directly explains the change in
neutralization phenotype remains to be determined.Materials and methods
Viral constructs
Full-length env genes of HIV-1 BL01 and BR07 were
cloned from blood and brain tissue, respectively, of two
HIV-1-infected patients as previously described (Ohagen et
al., 2003). The env genes were amplified from genomic
DNA at end point dilution by nested polymerase chain
reaction (PCR) and were cloned into the pSVIIIenv
expression plasmid by replacement of the 2.1 kb KpnI to
BamHI HxB2 env fragment. The resulting Env plasmids
contained the gp160 coding region of the cloned env except
for 36 amino acids at the N-terminus and 105 amino acids at
the C-terminus, which were derived from the HxB2 env
gene. The 89.6 envelope gene was cloned into the
pSVIIIenv plasmid in a similar manner. Replication com-
petent molecular clones were constructed by subcloning the
KpnI to BamHI env gene regions into the infectious NL4-3
plasmid (Ohagen et al., 2003). Thus, for each of the three
env genes, an Env expression plasmid and corresponding
chimeric IMC were created.
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stocks
Replication competent clonal virus stocks were generated
by transfection of human embryonic kidney 293T cells with
the chimeric infectious plasmids. Transfection of 293T cells
was performed using FuGene (Roche Molecular Biochem-
icals); medium was replaced after 24 h and supernatants
harvested at 48 h. Viral supernatants were clarified by
centrifugation, filtered through a 0.45 Am filter and stored in
aliquots at 70 -C. PBMC-derived viral stocks were
generated by a single passage of the 293T cell virus stock
into mitogen-stimulated PBMC, using previously described
culture conditions (Mascola et al., 2002). PBMC were
exposed to virus overnight and then washed to remove the
viral inoculum. Based on known replication kinetics, two
viruses (BL01 and BR07) were harvested on day 4,
representing the earliest time point that a high level of
infectious virus could be harvested. For HIV-1 89.6, the
culture media was replaced on day 4, and virus supernatants
were harvested on day six. Thus, the PBMC-derived virus
stocks were passaged through PBMC for no more than 4 to
6 days total. The IMCs derived directly from the 293T cells
are denoted as IMC-293T. After passage into PBMC, the
designation is IMC-PBMC.
Recombinant Env-pseudotyped green fluorescent pro-
tein (GFP) reporter viruses were generated by co-trans-
fection of 293T cells with the pNL4-3env plasmid (full-
length NL4-3 HIV proviral DNA with a frameshift in env
and encoding GFP in place of nef) and the pSVIIIenv
plasmid, encoding the 89.6, BL01 or BR07 Env protein
(He et al., 1997). The ratio of pNL4-3env plasmid DNA
to pSVIIIenv plasmid DNA was optimized at a 5:1 ratio by
weight. This ratio was shown to produce Env pseudovirus
stocks with the highest level of cell entry. Supernatant was
replaced at 24 h and harvested at 48 h.
Sequencing of full-length HIV-1 env genes
To sequence the HIV-1 env gene from PBMC-cultured
virus, proviral DNA was extracted from PBMC using the
QIAamp DNA Mini Kit from Qiagen, Inc. (Chatsworth,
CA) Full-length gp160 genes were amplified using HF Taq
polymerase (Invitrogen, Carlsbad, CA) and the following
primer pair: env A [5V-CACCGGCTTAGGCATCTC-3V] and
env M [5V-TAGCCCTTCCAGTCCCCC-3V]. PCR products
were visualized by agarose gel electrophoresis and purified
with the MinElute PCR Purification kit from Qiagen. Both
strands of PCR amplicons were directly sequenced using
dye terminator methods. Reactions were run on an ABI
3100 capillary sequencer, and DNA sequences were
assembled and edited using Sequencing Analysis (ABI)
and Sequencher 3.1 (Genecodes, Ann Arbor, MI) software.
The HIV-1 env gene insert in the pSVIIIenv expression
plasmids and in the full-length chimeric molecular clones
were amplified and sequenced using the same methods.Antibody reagents
Anti-HIV-1 human mAb IgG1b12 binds to the CD4
binding region of gp120 (Burton et al., 1994) and was
provided by Dennis Burton (Scripps, La Jolla, CA). IgG1
human mAbs 2F5, 4E10 and 2G12 were provided by
Hermann Katinger (Polymun Scientific, Vienna). mAb
2G12 recognizes a carbohydrate-dependent conformation-
ally sensitive region of gp120 outside the CD4 binding site
(Sanders et al., 2002; Scanlan et al., 2002; Trkola et al.,
1996); mAbs 2F5 and 4E10 bind to linear epitopes in the
ectodomain of gp41, near the transmembrane region of the
molecule (Parker et al., 2001; Purtscher et al., 1996; Zwick
et al., 2001). Anti-V3 mAb 447 and 2442 were provided by
Susan Zolla-Pazner (New York Veterans Affairs Medical
Center). Both anti-V3 mAbs neutralize some primary HIV-1
strains (Gorny et al., 2002, 2004). Two domain sCD4 was
contributed by Pharmacia and obtained from the NIH AIDS
Research and Reference Reagent Program. HIVIG (manu-
factured as HIV-IG by NABI, Boca Raton, FL) is a
preparation of purified IgG derived from the pooled plasma
of multiple HIV-1 seropositive donors as previously
described (Lambert et al., 1997).
Neutralization assays
Virus neutralization assays were performed using a flow
cytometric single round infection assay as previously
described (Mascola et al., 2002). This assay detects HIV-
1-infected T-cells by intracellular staining for HIV-1 p24-
Gag antigen (p24-Gag, used for IMC) or expression of GFP
(used for pseudovirions). For studies of virus stocks
produced from IMC, an HIV-1 protease inhibitor was used
to prevent secondary rounds of virus replication. The target
cells in all assays were phytohemagglutinin (PHA) and IL-
2-stimulated PBMC that had been depleted of CD8+ T-cells.
Briefly, 40 Al/well of HIV-1 virus stock (multiplicity of
infection ¨0.1) was incubated with 10 Al of antibody in 96-
well plates. After a 30 min incubation, 20 Al of activated
CD4 T-cells (1.5105 cells) was added to each well.
Approximately 48 h after virus infection, the T-cells were
harvested for flow cytometric analysis. For detection of
IMC infection, the cells were fixed and permeabilized using
the Cytofix/Cytoperm Kit (BD-PharMingen, San Diego,
CA) and were stained with a phycoerythrin (PE)-conjugated
mouse anti-p24 mAb (KC57-RD1, Beckman Coulter, Inc.).
Env pseudovirus-infected cells were analyzed for expression
of GFP. Cells were analyzed with a FACS Calibur flow
cytometer (Becton Dickinson), and data analysis was
performed with FlowJo software (Tree Star, Inc.). Approx-
imately 50,000 live cells, initially gated by forward and side
scatter, were analyzed for p24-Gag (or GFP) expression.
The percent virus neutralization mediated by each antibody
was derived by calculating the reduction in the number of
HIV-1-infected cells compared to control wells with no
antibody. To calculate the concentration of antibody that
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dose–response curves were fit with a nonlinear function
(four parameter logistic equation) using GraphPad Prism
software (GraphPad Software Inc. San Diego, CA).
Statistical analysis
To determine if IC50 values for antibody–virus combi-
nations were statistically different, replicate dose–response
curves for each antibody–virus were input into GraphPad
Prism statistical software. The mean dose–response curve
was fit by regression analysis using a four parameter logistic
equation known as a variable slope sigmoid equation. The
resulting IC50 value has an inherent standard error, and this
can be used to compare the IC50 value to that of a different
dose–response curve.
Quantitative measurements of viral protein content
Well characterized preparations of SIVMne/HuT-78
cl.E11S and HIV-1MN/H9 cl.4 (AIDS Vaccine Program,
AVP, Frederick, MD), and purified recombinant vaccinia
virus produced HIV-1MN gp120 (generously provided by
Drs. B. Puffer and R. Doms, University of Pennsylvania)
and purified native HIV-1MN p24 (AIDS Vaccine Program,
AVP, Frederick, MD) served as control reagents for
biochemical analyses of the virus preparations used in
neutralization studies. To produce enough virus for bio-
chemical analysis, each virus stock (IMC-293T, IMC-
PBMC and Env pseudovirus) was produced in relatively
large volume; i.e., 250 ml of virus stock. For each of the
nine virus stocks, 50 ml was reserved for titration and
neutralization experiments, and 200 ml was used for
biochemical analysis. Prior to biochemical analysis, viruses
were purified from clarified cell culture supernatants and
concentrated by ultracentrifugation through a sucrose pad in
a SW28 rotor at 112,700g followed by resuspension of the
resulting pellet and repelleting at 234,745g in a SW41
rotor (Chertova et al., 2002).
Proteins from lysed virus preparations were resolved by
SDS-PAGE on 4–20% gels (Invitrogen, Carlsbad, CA)
under reducing conditions. For estimation of p24 and gp120
content and the Gag:Env (p24:gp120) ratio for each virus
preparation (Chertova et al., 2002, Zhu et al., 2003), gels
containing resolved proteins for test and control viruses,
along with lanes containing known amounts of purified
gp120 and p24 standards quantitated by amino acid
analysis, were stained with Coomassie brilliant blue or with
fluorescent dyes, using SYPRO Pro-Q Emerald to detect
and quantitate glycoproteins and SYPRO Ruby for total
proteins (Molecular Probes, Eugene, OR). Stained gels were
analyzed, and integrated fluorescence intensity of bands for
p24 and gp120 determined using a VersaDoc 3000 Imaging
System (Bio-Rad Laboratories). The gp120 and p24 content
of each test sample were estimated based on interpolation of
the integrated fluorescence measured for each band onto thecorresponding titration curve obtained using purified gp120
or p24 protein standards. Where necessary, gel loading was
adjusted to obtain sufficient signal for interpolation of the
band of interest onto the linear portion of the relevant
standard curve. All estimates were based on interpolation of
integrated signals for test samples onto standard curves
derived from the same gels.Acknowledgments
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